» Articles » PMID: 23630355

Radiation-induced Equilibrium is a Balance Between Tumor Cell Proliferation and T Cell-mediated Killing

Overview
Journal J Immunol
Date 2013 May 1
PMID 23630355
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Local failures following radiation therapy are multifactorial, and the contributions of the tumor and the host are complex. Current models of tumor equilibrium suggest that a balance exists between cell birth and cell death due to insufficient angiogenesis, immune effects, or intrinsic cellular factors. We investigated whether host immune responses contribute to radiation-induced tumor equilibrium in animal models. We report an essential role for immune cells and their cytokines in suppressing tumor cell regrowth in two experimental animal model systems. Depletion of T cells or neutralization of IFN-γ reversed radiation-induced equilibrium, leading to tumor regrowth. We also demonstrate that PD-L1 blockade augments T cell responses, leading to rejection of tumors in radiation-induced equilibrium. We identify an active interplay between tumor cells and immune cells that occurs in radiation-induced tumor equilibrium and suggest a potential role for disruption of the PD-L1/PD-1 axis in increasing local tumor control.

Citing Articles

The Combined Prognostic Value of F-FDG PET/CT Metabolic Parameters of Immune Organs and Hematological Immune-Related Markers in Patients With Locally Advanced Cervical Cancer.

Li Y, Wang X, Li Y, Li W, Liu D, Guo L Cancer Med. 2025; 14(3):e70650.

PMID: 39912427 PMC: 11800136. DOI: 10.1002/cam4.70650.


EZH2 elicits CD8 T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.

Zhu C, Zhai T, Su M, Pan H, Tang Q, Huang B Commun Biol. 2024; 7(1):1645.

PMID: 39702756 PMC: 11659476. DOI: 10.1038/s42003-024-07341-9.


Understanding the PULSAR effect in combined radiotherapy and immunotherapy using transformer-based attention mechanisms.

Peng H, Moore C, Saha D, Jiang S, Timmerman R Front Oncol. 2024; 14:1497351.

PMID: 39687891 PMC: 11647037. DOI: 10.3389/fonc.2024.1497351.


Systemic immune-related spleen radiomics predict progression-free survival in patients with locally advanced cervical cancer underwent definitive chemoradiotherapy.

Li Y, Guo L, Xie P, Liu Y, Li Y, Liu A BMC Med Imaging. 2024; 24(1):310.

PMID: 39548404 PMC: 11568675. DOI: 10.1186/s12880-024-01492-1.


Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer.

Yamanaka Y, Ota T, Masuoka Y, Takeyasu Y, Nakamura S, Terashima M Cancers (Basel). 2024; 16(18).

PMID: 39335099 PMC: 11430718. DOI: 10.3390/cancers16183127.


References
1.
Char D, Kroll S, Phillips T, Quivey J . Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology. 2002; 109(10):1850-4. DOI: 10.1016/s0161-6420(02)01174-0. View

2.
Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

3.
Lugade A, Sorensen E, Gerber S, Moran J, Frelinger J, Lord E . Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008; 180(5):3132-9. DOI: 10.4049/jimmunol.180.5.3132. View

4.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

5.
Klein C . Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev. 2010; 21(1):42-9. DOI: 10.1016/j.gde.2010.10.011. View